Inflammatory markers predict survival in patients with postoperative urothelial carcinoma receiving tislelizumab (PD-1 inhibitor) adjuvant therapy
Abstract Background In the management of urothelial carcinoma, patient selection for immunotherapy, particularly with immune checkpoint inhibitors such as PD-1 (programmed cell death protein 1), is important for treatment efficacy. Inflammatory markers are useful for predicting treatment outcomes an...
保存先:
| 主要な著者: | , , , , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
BMC
2024-02-01
|
| シリーズ: | BMC Cancer |
| 主題: | |
| オンライン･アクセス: | https://doi.org/10.1186/s12885-024-11969-5 |
| タグ: |
タグなし, このレコードへの初めてのタグを付けませんか!
|